Beta Drugs Ltd. · NSE:BETA
Beta Drugs — Investor Presentation (December 2021)
24 slides from Beta Drugs's investor presentation, Dec 3, 2021
Slide 1: Beta Drugs Ltd
B E TA D R U G S LT D
Slide 2: Disclaimer
Disclaimer • This corporate presentation has been prepared by Beta Drugs Limited (the “Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. • This presentation should not be construed as legal, tax,
Slide 3: Our Genesis
Our Genesis The Journey of Beta Drugs Limited began early 80’s with the ardent efforts of Late Shri Vijay Kumar Batra. He was a visionary and businessman par excellence. He had foreseen the scope in niche segment like Oncology and laid the foundation of Indian Pharma Multinational in Oncology segmen
Slide 4: Milestones
Milestones Set up a new “state of art” Setup In-house PFS facility manufacturing facility for Oncology Launched GEM-RTU, ADLEAP formulations- Beta Drugs Limited (Enzalutamide), Launched 1st Laid the foundation of Indian Brand of Dasatinib Adley group by Late Shri Received SME Excellence Award BEEDAN
Slide 5: Our Strength: Formulations and API Plant
Our Strength Formulations and API Plant Beta Drugs Ltd Adley Formulations Pvt Ltd Beta Drugs Ltd Capacity: 3.5 million injection & ampoules WHO- GMP plant & other international 50 million Tablets & 10 million capsules accreditations. Triggered for INVIMA & PICS Beta Drugs Ltd- UBK Capacity: 43 milli
Slide 6: Our Market Reach - Domestic Market
Our Market Reach- Domestic Market Beta drugs Limited has strong position in Indian market with 101 SKUs. Products are available in major corporate & Govt hospitals
Slide 7: Our Product Portfolio
&\ Our Product Portfolio e.) BETA DRUGS LTD. Soli Tumor ADSUNIB @apteaP BEXINIB — CAPAD ADOXI ADPLATIN ADVIN Adlante Gem-RTU AMGICIN ADGEF — ERLOTAD TEMOZAD__INOTAD Lwin Capes VIO Mg Comair 200mg, emai 2001000, Gein abs 250mg (tin Tablets 100/150, Tecan Caps 20100250 mg —_‘Winotecan In 1O0mg/Sia HER
Slide 8: Leading position in Oncology
Domestic Market Finished Formulation Sales (Cr) Domestic Formulation Sales Leading position in Oncology 2 Brands occupy No 1 position in India 6 New brands launched in FY 21-22 New brands to be launched in 4th Qtr of FY 4 21-22 to strengthen Haematology basket Exclusively dedicated to Oncology
Slide 9: Current Position in Own Brand Sales
Domestic Market Inhouse developed NNDS of Inj Azacitidine Current Position in Own Brand Sales Oncology division overview • Currently operating with 58 Molecules & 101 SKUs • Sales and Marketing of product is supported by 36 Sales representatives and strategically located logistics network of over 12
Slide 10: Our Market Reach - International Branded Markets
Our Market Reach- International Branded Markets BDL is first Indian company to manufacture Oncology drugs in Uzbekistan Globally represented by our subsidiaries or sales partners in over 16 Countries More than 50 products have been registered BDL is also planning to file 1st DMF by October 2022 thro
Slide 11: Our International Regulatory Accreditations
Our International Regulatory Accreditations Our regulatory department works on the guidelines of CTD and ICH. Our team is engaged in day to day development of dossiers - DMFs, interacting with all the manufacturing sites to keep updating them for regular regulatory developments and features in the i
Slide 12: Our Strength - Strong In-House API Development
Our Strength – Strong In-House API Development VERTICAL INTEGRATION API STRENGTH COMPANY’S FOCUS: • Complex Multi-Step Synthesis & Scale Up • To launch APIs in the cytotoxic segment • Containment & High Potency APIs • To be the first few players in the entry of new TKI’s • Scale up of production Cap
Slide 13: Our Strength - Strong In-House API Development
Our Strength – Strong In-House API development SOLID TUMOR HEMATOLOGY SUPPORTIVE ANASTROZOLE AZACITIDINE APREPITANT AXITINIB AZACITIDINE- ORAL FOSAPREPITANT BICALUTAMIDE BENDAMUSTINE ZOLEDRONIC ACID DOCETAXEL TRIHYDRATE BORTEZOMIB ENZALUTAMIDE DASATINIB ERLOTINIB HYDROCHLORIDE HYDROXYUREA FULVESTRAN
Slide 14: Our Indian CMO Partners
Our Indian CMO Partners BDL is acknowledged as a high quality manufacturing company by many leading pharmaceutical companies in India. BDL has impressive clientele base of more than 70 Indian companies.
Slide 15: Our Strength - Strong Research & Development (R&D)
Our Strength – Strong Research & Development (R&D) Strong R&D capabilities demonstrated by its complex oncology formulations & oncology APIs Highly accomplished team of dedicated scientists for process and analytical work, Pre-formulation studies, Physico-Chemical New Product Pipeline Characterizati
Slide 16: Growth Drivers
Growth Drivers Branded Formulation API Contract manufacturing Domestic International - Enter in new geographies New Product approval Partnership with over 70 Growth Drivers - New brand launches Indian Pharma companies - Increased business from - Registration of new Facility expansion New product app
Slide 17: Highlights: Apr'21-Sep'21
Highlights : Apr’21- Sep’21 Recent Highlights Continuous expansion Pivotal growth in in Oncology Portfolio Emerging Brands Domestic market New Approvals Brands launched in FY21-22 Brands which gained rank and became top 5 player Domestic Sales WHO-GMP approval for API plant In-house development of 2
Slide 18: Strategic Focus
Strategic Focus Expanding capacity to meet future demand of Domestic formulation, contract manufacturing & API Be the First to Launch(FTL) Deepen go- to market model: Demand generation for oncology Upgraded facilities products in Corporate & private to get the international hospitals accreditations
Slide 19: Financial Performance
Financial Performance REVENUE INR 88.6 Cr 71% YoY EBITDA INR 20.5 Cr 23% 87% YoY H1 FY 22 Consolidated Revenue Break up Actual Vs H1 API H1 FY’22(Rs Cr) FY’21 5% Domestic 27% Total revenue 88.6 71% Contract manufacturing + International EBTIDA 20.5 87% indirect exports 10% 58% EBITA % 23.1 % 197 bps
Slide 20: Financial Performance
Financial Performance Sustainable Financial Performance over the years ------------------------------------------------------------------------------ %EBITDA 22% 23% 20% 18% FY'19 FY'20 FY'21 H1 FY' 22 --------------------------------------------------------------------------------------------------
Slide 21: Solvency Ratio
Solvency Ratio Sustainable Financial Performance over the years --------------------------------- Debt Ratio 0.48 Debt to equity ratio 0.24 0.21 0.39 0.14 0.25 0.12 0.21 FY'19 FY'20 FY'21 H1 FY' 22 FY'19 FY'20 FY'21 H1 FY' 22 --------------------------------------------------------------------------
Slide 22: FY21-22 Priorities
FY21-22 PRIORITIES
Slide 23: FY'22 Priorities
FY’22 Priorities Domestic Market International market Operations Launch of New products – Azacitidine Oral, Focus on new tie-up’s in countries with Strengthen quality management systems Pazopanib , Afatinib & Carfilzomib existing business and processes Focus on Railway, CGHS, Army to increase Commer
Slide 24: Innovative product development is a result of our sustained efforts
Innovative product development is a result of our sustained efforts. Contacts Email: sales@betadrugslimited.com Email: info@betadrugslimited.com